| Primary |
| Non-small Cell Lung Cancer |
22.9% |
| Prophylaxis |
11.4% |
| Lung Adenocarcinoma |
9.3% |
| Lung Neoplasm Malignant |
9.0% |
| Vitamin Supplementation |
6.5% |
| Lung Adenocarcinoma Stage Iv |
5.1% |
| Supplementation Therapy |
4.7% |
| Premedication |
4.1% |
| Pleural Mesothelioma Malignant |
3.6% |
| Hypertension |
3.3% |
| Pain |
3.1% |
| Mesothelioma |
3.0% |
| Prophylaxis Of Nausea And Vomiting |
2.1% |
| Non-small Cell Lung Cancer Stage Iv |
2.0% |
| Lung Adenocarcinoma Metastatic |
2.0% |
| Non-small Cell Lung Cancer Metastatic |
1.9% |
| Pleural Mesothelioma |
1.7% |
| Lung Cancer Metastatic |
1.6% |
| Constipation |
1.5% |
| Adenocarcinoma |
1.4% |
|
| Death |
13.1% |
| Thrombocytopenia |
10.9% |
| Vomiting |
6.2% |
| Pyrexia |
5.9% |
| Pancytopenia |
5.7% |
| White Blood Cell Count Decreased |
5.5% |
| Malignant Neoplasm Progression |
5.2% |
| Rash |
5.0% |
| Interstitial Lung Disease |
4.9% |
| Off Label Use |
4.8% |
| Renal Failure |
4.3% |
| Pneumonia |
3.9% |
| Myocardial Infarction |
3.8% |
| Sepsis |
3.7% |
| Neutropenia |
3.2% |
| Neoplasm Progression |
3.1% |
| Pulmonary Embolism |
3.0% |
| Respiratory Failure |
2.6% |
| Weight Decreased |
2.6% |
| Hospitalisation |
2.5% |
|
| Secondary |
| Non-small Cell Lung Cancer |
27.9% |
| Drug Use For Unknown Indication |
13.4% |
| Prophylaxis |
11.5% |
| Lung Adenocarcinoma |
9.9% |
| Product Used For Unknown Indication |
5.2% |
| Lung Neoplasm Malignant |
4.7% |
| Pleural Mesothelioma Malignant |
3.8% |
| Pain |
2.6% |
| Hypertension |
2.5% |
| Premedication |
2.4% |
| Head And Neck Cancer |
2.3% |
| Non-small Cell Lung Cancer Stage Iv |
2.3% |
| Lung Adenocarcinoma Metastatic |
1.8% |
| Nausea |
1.6% |
| Vitamin Supplementation |
1.5% |
| Pleural Mesothelioma |
1.4% |
| Lung Cancer Metastatic |
1.3% |
| Chemotherapy |
1.3% |
| Non-small Cell Lung Cancer Metastatic |
1.3% |
| Cancer Pain |
1.3% |
|
| Thrombocytopenia |
15.2% |
| White Blood Cell Count Decreased |
10.2% |
| Vomiting |
8.0% |
| Interstitial Lung Disease |
6.5% |
| Renal Failure |
5.5% |
| Pyrexia |
5.4% |
| Sepsis |
4.7% |
| Pancytopenia |
4.5% |
| Death |
4.3% |
| Anaemia |
3.8% |
| Neutropenia |
3.7% |
| Renal Failure Acute |
3.7% |
| Pneumonia |
3.3% |
| Weight Decreased |
3.3% |
| Dyspnoea |
3.2% |
| Rash |
3.2% |
| Respiratory Failure |
3.2% |
| Platelet Count Decreased |
2.8% |
| Mucosal Inflammation |
2.7% |
| Pulmonary Embolism |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.6% |
| Non-small Cell Lung Cancer |
14.0% |
| Lung Adenocarcinoma Metastatic |
7.4% |
| Drug Use For Unknown Indication |
6.7% |
| Lung Adenocarcinoma |
6.4% |
| Lung Neoplasm Malignant |
6.4% |
| Lung Adenocarcinoma Recurrent |
5.3% |
| Nausea |
4.1% |
| Pain |
3.5% |
| Metastases To Bone |
3.4% |
| Adenosquamous Cell Lung Cancer |
3.4% |
| Vomiting |
2.4% |
| Prophylaxis |
1.8% |
| Chemotherapy |
1.7% |
| Prophylaxis Of Nausea And Vomiting |
1.6% |
| Blood Magnesium Decreased |
1.6% |
| Dyspepsia |
1.6% |
| Hypersensitivity |
1.6% |
| Hypertension |
1.3% |
| Depression |
1.2% |
|
| White Blood Cell Count Decreased |
9.2% |
| Disease Progression |
7.0% |
| Death |
6.6% |
| Fatigue |
6.6% |
| Pneumonia |
6.6% |
| Pulmonary Embolism |
5.7% |
| Toothache |
5.7% |
| Alanine Aminotransferase Increased |
5.3% |
| Embolism Arterial |
5.3% |
| Lung Neoplasm Malignant |
5.3% |
| Vomiting |
4.8% |
| Pyothorax |
4.4% |
| Sepsis |
4.4% |
| Tachycardia |
4.4% |
| Osteonecrosis |
3.9% |
| Hypertension |
3.5% |
| Respiratory Failure |
3.1% |
| Thrombocytopenia |
3.1% |
| Hyponatraemia |
2.6% |
| Myocardial Infarction |
2.6% |
|
| Interacting |
| Drug Use For Unknown Indication |
100.0% |
|
| Transaminases Increased |
100.0% |
|
